Liminatus Advances Next-Gen CD47 Inhibitor Toward Human Trials In U.S. and Korea, Targeting Safer Immunotherapy; Eyes 2026 IND Filings For CD47 Inhibitor

Next-generation CD47 inhibitor advances toward human trials in U.S. and Korea, with the prospect of safer, more potent immunotherapy.

Since its Nasdaq debut earlier this year, Liminatus Pharma has been preparing to redefine the immune-oncology landscape with IBA101, a novel CD47 checkpoint inhibitor engineered to eliminate the anemia and thrombocytopenia that halted earlier candidates. By sparing red blood cells and platelets through targeted epitope selection and Fc engineering, IBA101 enables higher dosing levels—potentially unlocking more robust anti‑tumor responses without compromising patient safety.

Behind the scenes, the company is preparing its IND-enabling package after completing pivotal GLP toxicology and pharmacology studies in non‑human primates at Charles River Laboratories, as well as downstream process development for clinical‑grade production. These data indicated that IBA101 did not induce clinically meaningful reductions in hemoglobin or platelet counts, clearing the path for simultaneous submissions to the U.S. Food and Drug Administration (FDA) and Korea's Ministry of Food and Drug Safety (MFDS) in the second half of 2026. Liminatus anticipates site activations and patient screening to begin in early 2027.

About Liminatus Pharma
Liminatus Pharma (NASDAQ:LIMN) is a preclinical‑stage immuno‑oncology company advancing IBA101 toward best‑in‑human trials. Building on over a decade of CD47 research and lessons learned from industry setbacks, Liminatus's mission is to develop next‑generation immunotherapies that restore immune balance—bridging innate and adaptive immunity to drive safer, more durable anti‑tumor responses.